Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04445519 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
A Phase 3 study, sponsored by Nicox Ophthalmics.
- Completed
- Registry status
- Phase 3
- Development phase
- 691
- Enrollment target
NCT04445519 is a Phase 3 study that has completed, run by Nicox Ophthalmics. The registered enrollment target is 691 participants.
The verdict
NCT04445519, a Phase 3 study, has completed, sponsored by Nicox Ophthalmics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 691 participants
- Enrollment target
Study Summary
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. In the adaptive dose selection phase of the trial, subjects will be randomized in a 1:1:1 ratio to one of two doses of NCX 470 (0.065% or 0.1%) or to latanoprost 0.005%. Following the selection of one dose of NCX 470, subjects will be randomized in a 1:1 ratio to the chosen dose of NCX 470 or to latanoprost 0.005%.
Interventions
- DRUG NCX 470 0.065% (initial phase of trial)
- DRUG Latanoprost 0.005% (initial phase of trial)
- DRUG NCX 470 0.1% (initial phase of trial)
- DRUG NCX 470 0.1% (remainder of trial)
- DRUG Latanoprost 0.005% (remainder of trial)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 691 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2022-09-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04445519
The ClinicalTrials.gov registry entry for NCT04445519 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 691 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nicox Ophthalmics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which NCX 470 0.065% (initial phase of trial) is the first listed.
NCT04445519 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04445519 about?
NCT04445519 is a clinical study titled "Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension". The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. In the adaptive dose selection phase of the trial, subjects will be randomized in a 1:1:1 rat...
What is the current status of trial NCT04445519?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 691 participants. The study started on 2020-06-01. Estimated completion is 2022-09-16.
What interventions are being tested in trial NCT04445519?
The interventions under investigation include: NCX 470 0.065% (initial phase of trial) (DRUG), Latanoprost 0.005% (initial phase of trial) (DRUG), NCX 470 0.1% (initial phase of trial) (DRUG), NCX 470 0.1% (remainder of trial) (DRUG), Latanoprost 0.005% (remainder of trial) (DRUG).
Who is sponsoring clinical trial NCT04445519?
This trial is sponsored by Nicox Ophthalmics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.